MétaCan
Menu
Back to cohort
Record W3127097750 · doi:10.1158/2159-8290.cd-20-1050

Mutations in the RAS/MAPK Pathway Drive Replication Repair–Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition

2021· article· en· W3127097750 on OpenAlexafffund
Brittany Campbell, Melissa A. Galati, Simone C. Stone, Alexandra N. Riemenschneider, Melissa Edwards, Sumedha Sudhaman, Robert Siddaway, Martin Komosa, Nuno M. Nunes, Liana Nobre, A. Sorana Morrissy, Matthew Zatzman, Michal Zápotocký, Lazar Joksimovic, Sangeetha Kalimuthu, David Samuel, Gary Mason, Éric Bouffet, Daniel A. Morgenstern, Melyssa Aronson, Carol Durno, David Malkin, John M. Maris, Michael D. Taylor, Adam Shlien, Trevor J. Pugh, Pamela S. Ohashi, Cynthia Hawkins, Uri Tabori

Bibliographic record

VenueCancer Discovery · 2021
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicMelanoma and MAPK Pathways
Canadian institutionsOntario Institute for Cancer ResearchMount Sinai HospitalUniversity Health NetworkUniversity of TorontoAlberta Cancer FoundationPrincess Margaret Cancer CentreHospital for Sick Children
FundersStand Up To CancerOntario Genomics InstituteGovernment of CanadaCanadian Institutes of Health ResearchOntario GenomicsGenome CanadaNational Cancer InstituteEntertainment Industry FoundationGarron Family Cancer CentreAmerican Association for Cancer ResearchBristol-Myers SquibbGovernment of Ontario
KeywordsMutationMAPK/ERK pathwayGeneticsCancer researchBiologyReplication (statistics)Cell biologySignal transductionGeneVirology

Abstract

fetched live from OpenAlex

Abstract The RAS/MAPK pathway is an emerging targeted pathway across a spectrum of both adult and pediatric cancers. Typically, this is associated with a single, well-characterized point mutation in an oncogene. Hypermutant tumors that harbor many somatic mutations may obscure the interpretation of such targetable genomic events. We find that replication repair–deficient (RRD) cancers, which are universally hypermutant and affect children born with RRD cancer predisposition, are enriched for RAS/MAPK mutations (P = 10−8). These mutations are not random, exist in subclones, and increase in allelic frequency over time. The RAS/MAPK pathway is activated both transcriptionally and at the protein level in patient-derived RRD tumors, and these tumors responded to MEK inhibition in vitro and in vivo. Treatment of patients with RAS/MAPK hypermutant gliomas reveals durable responses to MEK inhibition. Our observations suggest that hypermutant tumors may be addicted to oncogenic pathways, resulting in favorable response to targeted therapies. Significance: Tumors harboring a single RAS/MAPK driver mutation are targeted individually for therapeutic purposes. We find that in RRD hypermutant cancers, mutations in the RAS/MAPK pathway are enriched, highly expressed, and result in sensitivity to MEK inhibitors. Targeting an oncogenic pathway may provide therapeutic options for these hypermutant polyclonal cancers. This article is highlighted in the In This Issue feature, p. 1307

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.081
Threshold uncertainty score0.344

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.256
Teacher spread0.242 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations39
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueCancer DiscoverySame topicMelanoma and MAPK PathwaysFrench-language works237,207